0
Deep & Emerging Tech·November 16, 2026·1 min read

The FDA declined to approve one of biotech’s most closely watched cancer drugs

Share

The FDA pushing back on a closely watched lung-cancer drug until it shows overall survival benefit is a reminder that surrogate endpoints and hype don’t clear regulators. If you’re building AI in drug discovery or clinical decision support, anchor your value story on hard outcomes regulators already trust.